Dr. Ellis on Measuring Endocrine Therapy Efficacy

Matthew J. Ellis, MD, PhD
Published: Tuesday, Sep 06, 2011

Matthew J. Ellis, MD, PhD, director, Section of Breast Oncology, Division of Oncology, Department of Medicine, Washington University, St Louis, MO, discusses determining the efficacy of endocrine therapy by measuring the Ki67 cell-proliferation marker after a few weeks of receiving therapy.

Ellis explains that endocrine therapy resistant ER-positive disease is the highest cause of deaths in breast cancer. By finding tumors that do not respond to endocrine therapy early on by using the Ki67 marker you can change therapies early in the treatment process.
Matthew J. Ellis, MD, PhD, director, Section of Breast Oncology, Division of Oncology, Department of Medicine, Washington University, St Louis, MO, discusses determining the efficacy of endocrine therapy by measuring the Ki67 cell-proliferation marker after a few weeks of receiving therapy.

Ellis explains that endocrine therapy resistant ER-positive disease is the highest cause of deaths in breast cancer. By finding tumors that do not respond to endocrine therapy early on by using the Ki67 marker you can change therapies early in the treatment process.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x